AstraZeneca Claims First Global Pharma Slot in China's Cell Therapy Manufacturing

The British drugmaker said Thursday it will build a cell therapy manufacturing and supply base and an innovation centre in Shanghai, aiming to become the first global pharmaceutical company with end-to-end cell therapy capabilities inside China.

The facility will produce and supply CAR-T cell therapies targeting both the Chinese market and other Asian countries, according to a company statement on its Chinese social media account. CAR-T treatments modify a patient's own immune cells to recognize and kill cancer cells.

The move is the latest deployment of AstraZeneca's $15 billion China investment commitment through 2030, announced in January during UK Prime Minister Keir Starmer's visit to Beijing. AstraZeneca CEO Pascal Soriot called it the company's largest investment in China to date.

"China was a recognised leader" in cell therapy and radioconjugates, AstraZeneca said at the time. The Shanghai facility builds on the company's 2024 acquisition of Gracell Biotechnologies, a deal that gave AstraZeneca a BCMA/CD19 CAR-T platform and made it the first global biopharma with end-to-end cell therapy capabilities in China pending regulatory approvals.

Thursday's announcement also included plans for a radioconjugate drug production and supply base in Guangzhou, southern China, to provide cancer treatments across the Asia-Pacific region.

The investments underscore AstraZeneca's continued bet on China even as some rival Western drugmakers have divested Chinese assets amid supply chain concerns, economic headwinds, and pricing pressure from China's centralized drug procurement system.

China accounts for roughly 12% of AstraZeneca's global revenue. The company has operated in the country for more than 30 years and employs more than 20,000 people there across sites in Wuxi, Taizhou, Qingdao, Beijing, and Shanghai. Those facilities supply medicines to China and 70 markets worldwide.

The timing is notable. While AstraZeneca is simultaneously deploying $50 billion toward US manufacturing — a deal announced last year — the China expansion signals that the world's second-largest pharmaceutical market remains central to Soriot's strategy. The company weathered a rough patch in China after the 2024 arrest of its then-China president Leon Wang, who was detained by Chinese authorities in connection with an investigation that reportedly involved alleged medical insurance fraud. AstraZeneca later appointed a replacement.

The $15 billion commitment was framed by Starmer's government as a win for British industry, with the prime minister saying it would "support thousands of UK jobs." For AstraZeneca, the prize is access to China's rapidly growing biotech ecosystem, which has become a prolific source of early-stage drug candidates. The company has signed more than a dozen partnerships with Chinese biotech firms including AbelZeta, CSPC, Harbour BioMed, Jacobio, and Syneron Bio.

The Shanghai cell therapy hub will work with more than 500 hospitals across China that already participate in AstraZeneca's clinical trial network — giving the company a domestic manufacturing advantage that foreign competitors currently lack.

Not everyone is convinced this is a clean strategic win. Western regulators have grown increasingly wary of pharmaceutical supply chain concentration in China, and Congress has pressed the FDA to assess dependencies on Chinese-manufactured drugs and active ingredients. AstraZeneca's bet that it can operate at scale in both Washington and Beijing simultaneously — while navigating geopolitical crosscurrents — will face continued scrutiny.

The company declined to specify the value of the Shanghai facility investment.

---

Sources:

https://www.reuters.com/business/healthcare-pharmaceuticals/astrazeneca-says-it-will-build-cell-therapy-base-innovation-centre-shanghai-2026-03-19/

https://www.reuters.com/business/healthcare-pharmaceuticals/astrazeneca-sets-out-15-billion-china-investment-during-starmer-visit-2026-01-29/